Old Web
English
Sign In
Acemap
>
authorDetail
>
Johanna Hyacinthe
Johanna Hyacinthe
Merck & Co.
Medicine
Hazard ratio
patient preference
Population
Myocardial infarction
3
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment.
2021
The Patient: Patient-Centered Outcomes Research
Cathy-Anne Pinto
G.N. Chua
John F.P. Bridges
Ella Brookes
Johanna Hyacinthe
Tommi Tervonen
Show All
Source
Cite
Save
Citations (0)
Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessment.
2021
Journal of Clinical Epidemiology
Tommi Tervonen
Thibaud Prawitz
Gin Nie Chua
Johanna Hyacinthe
Cathy-Anne Pinto
Show All
Source
Cite
Save
Citations (0)
Personalized benefit‐risk assessments combining clinical trial and real‐world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy
2019
Pharmacoepidemiology and Drug Safety
Cathy-Anne Pinto
Tommi Tervonen
Kevin Marsh
Dimitra Lambrelli
Anna Schultze
Andrew M. Tershakovec
Johanna Hyacinthe
Thibaud Prawitz
Tarek A. Hammad
Show All
Source
Cite
Save
Citations (5)
1